MiNK Therapeutics, Inc. (INKT)Healthcare | Biotechnology | New York, United States | NasdaqCM
11.43 USD
-0.35
(-2.986%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 11.30 -0.13 (-0.133%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:20 a.m. EDT
The immediate outlook remains neutral despite a recent bounce, as the statistical forecast model offers no directional edge with low confidence. While the stock has rallied sharply over the last year, the underlying business fundamentals are severely compromised by negative earnings, negative free cash flow, and a negative book value, indicating significant financial distress rather than sustainable growth. Furthermore, there is no dividend income to offset the capital risk, making this a speculative biotech play with no safety margin. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.057946 |
| AutoETS | 0.108227 |
| MSTL | 0.125227 |
| AutoTheta | 0.125364 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 7.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.279 |
| Excess Kurtosis | -1.17 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 58,318,128 |
| Forward P/E | -4.32 |
| Website | https://minktherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.15728718 |
| Address1 | 149 Fifth Avenue |
| Address2 | Suite 500 |
| All Time High | 221.55 |
| All Time Low | 4.56 |
| Ask | 14.59 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 9,400 |
| Average Daily Volume3 Month | 17,688 |
| Average Volume | 17,688 |
| Average Volume10Days | 9,400 |
| Bid | 7.89 |
| Bid Size | 2 |
| Book Value | -2.752 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.4282 |
| Current Ratio | 1.228 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 11.45 |
| Day Low | 11.06 |
| Display Name | MiNK Therapeutics |
| Earnings Call Timestamp End | 1,786,624,200 |
| Earnings Call Timestamp Start | 1,786,624,200 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -12,365,399 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.004 |
| Enterprise Value | 49,511,152 |
| Eps Current Year | -1.93 |
| Eps Forward | -2.645 |
| Eps Trailing Twelve Months | -2.3 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.265 |
| Fifty Day Average Change | 0.16319942 |
| Fifty Day Average Change Percent | 0.014487299 |
| Fifty Two Week Change Percent | -15.728718 |
| Fifty Two Week High | 16.98 |
| Fifty Two Week High Change | -5.5518 |
| Fifty Two Week High Change Percent | -0.32696113 |
| Fifty Two Week Low | 8.48 |
| Fifty Two Week Low Change | 2.9482002 |
| Fifty Two Week Low Change Percent | 0.34766513 |
| Fifty Two Week Range | 8.48 - 16.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,634,304,600,000 |
| Float Shares | 1,999,662 |
| Forward Eps | -2.645 |
| Forward P E | -4.3206806 |
| Free Cashflow | -5,245,477 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 15 |
| Fullday Change | -0.3518 |
| Fullday Change Percent | -2.98642 |
| Fullday Price | 11.295 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.59231 |
| Held Percent Institutions | 0.04006 |
| Implied Shares Outstanding | 5,103,002 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-15 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,738,022,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. |
| Long Name | MiNK Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 58,318,128 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1679217092 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -11,360,382 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 60,113,363 |
| Number Of Analyst Opinions | 2 |
| Open | 11.325 |
| Operating Cashflow | -6,830,483 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 212 994 8250 |
| Post Market Change | -0.13319969 |
| Post Market Change Percent | -1.1655352 |
| Post Market Price | 11.295 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 11.78 |
| Price Eps Current Year | -5.921347 |
| Price Hint | 2 |
| Price To Book | -4.1526885 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.164 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.35179996 |
| Regular Market Change Percent | -2.9864173 |
| Regular Market Day High | 11.45 |
| Regular Market Day Low | 11.06 |
| Regular Market Day Range | 11.06 - 11.45 |
| Regular Market Open | 11.325 |
| Regular Market Previous Close | 11.78 |
| Regular Market Price | 11.4282 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 6,788 |
| Return On Assets | -1.2933999 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,103,002 |
| Shares Percent Shares Out | 0.0153 |
| Shares Short | 78,320 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 99,574 |
| Short Name | MiNK Therapeutics, Inc. |
| Short Percent Of Float | 0.0307 |
| Short Ratio | 8.21 |
| Source Interval | 15 |
| State | NY |
| Symbol | INKT |
| Target High Price | 43.0 |
| Target Low Price | 35.0 |
| Target Mean Price | 39.0 |
| Target Median Price | 39.0 |
| Total Cash | 8,806,977 |
| Total Cash Per Share | 1.726 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 11.42271 |
| Two Hundred Day Average Change | 0.0054893494 |
| Two Hundred Day Average Change Percent | 0.00048056451 |
| Type Disp | Equity |
| Volume | 6,788 |
| Website | https://minktherapeutics.com |
| Zip | 10,010 |